中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 9
Sep.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(9): 2205-2209

Association between portal hypertension and malnutrition in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.09.026

  • Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research，Fourth Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Beijing Hospitals Authority’s Ascent Plan (DFL20221501);

Construction Project of High－level Technology Talents in Public Health (Discipline leader－01－12);

Beijing Municipal Natural Science Foundation (7222094)

More Information
  • Corresponding author: CHEN Yu， chybeyond1071@ccmu.edu.cn （ORCID： 0000－0001－7612－3240）; DUAN Zhongping， duan@ccmu.edu.cn （ORCID： 0000－0002－8455－0426）
  • Received Date: 2022-12-22
  • Accepted Date: 2023-02-03
  • Published Date: 2023-09-19
    Abstract
  • The abnormal histological structure of liver cirrhosis leads to the increase in portal venous pressure， and portal hypertension is the main cause of the decompensated events of liver cirrhosis such as ascites， gastroesophageal variceal bleeding， hepatic encephalopathy， and hepatorenal syndrome. Malnutrition is one of the most common complications in cirrhotic patients with portal hypertension， and the main causes of malnutrition include reduced nutrient intake， nutrient absorption disorders， hypermetabolism， hyperammonemia， and intestinal flora disturbance. There is an interaction between portal hypertension and malnutrition in liver cirrhosis， and this article briefly reviews the research advances in such interaction.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359－ 1376. DOI: 10.1016/S0140－6736(21)01374－X.
    [2]
    LAI JC, TANDON P, BERNAL W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74( 3): 1611－ 1644. DOI: 10.1002/hep.32049.
    [3]
    ENGELMANN C, CLÀRIA J, SZABO G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021, 75( Suppl 1): S49－S66. DOI: 10.1016/j.jhep.2021.01.002.
    [4]
    MERLI M. Nutrition in cirrhosis: Dos and Don’ts[J]. J Hepatol, 2020, 73( 6): 1563－ 1565. DOI: 10.1016/j.jhep.2020.07.019.
    [5]
    GLASS C, HIPSKIND P, TSIEN C, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study[J]. J Appl Physiol(1985), 2013, 114( 5): 559－ 565. DOI: 10.1152/japplphysiol.01042.2012.
    [6]
    TRAUB J, REISS L, ALIWA B, et al. Malnutrition in patients with liver cirrhosis[J]. Nutrients, 2021, 13( 2): 540. DOI: 10.3390/nu13020540.
    [7]
    YAO J, CHANG L, YUAN L, et al. Nutrition status and small intestinal bacterial overgrowth in patients with virus－related cirrhosis[J]. Asia Pac J Clin Nutr, 2016, 25( 2): 283－ 291. DOI: 10.6133/apjcn.2016.25.2.06.
    [8]
    MÜLLER MJ, BÖTTCHER J, SELBERG O, et al. Hypermetabolism in clinically stable patients with liver cirrhosis[J]. Am J Clin Nutr, 1999, 69( 6): 1194－ 1201. DOI: 10.1093/ajcn/69.6.1194.
    [9]
    LIU YY, CHEN DF, YAN QX. Current status of the pathogenesis, diagnosis, and treatment of sarcopenia in patients with liver cirrhosis[J]. J Clin Hepatol, 2022, 38( 1): 191－ 195. DOI: 10.3969/j.issn.1001－5256.2022.01.033.

    刘钰懿, 陈东风, 颜綦先. 肝硬化肌少症的发病机制与诊疗现状[J]. 临床肝胆病杂志, 2022, 38( 1): 191－ 195. DOI: 10.3969/j.issn.1001－5256.2022.01.033.
    [10]
    REN X, HAO S, YANG C, et al. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting[J]. Nutrition, 2021, 83: 111081. DOI: 10.1016/j.nut.2020.111081.
    [11]
    TSIEN C, ANTONOVA L, SUCH J, et al. Impact of bacterial translocation on sarcopenia in patients with decompensated cirrhosis[J]. Nutrients, 2019, 11( 10): 2379. DOI: 10.3390/nu11102379.
    [12]
    TOPAN MM, SPOREA I, DĂNILĂ M, et al. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis[J]. Front Nutr, 2021, 8: 766451. DOI: 10.3389/fnut.2021.766451.
    [13]
    DAJTI E, RENZULLI M, RAVAIOLI F, et al. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis[J]. Dig Liver Dis, 2023, 55( 5): 637－ 643. DOI: 10.1016/j.dld.2022.11.011.
    [14]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32( 2): 203－ 219. DOI: 10.3969/j.issn.1001－5256.2016.02.002.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32( 2): 203－ 219. DOI: 10.3969/j.issn.1001－5256.2016.02.002.
    [15]
    TSAI MH, HUANG HC, PENG YS, et al. Nutrition risk assessment using the modified NUTRIC score in cirrhotic patients with acute gastroesophageal variceal bleeding: Prevalence of high nutrition risk and its independent prognostic value[J]. Nutrients, 2019, 11( 9): 2152. DOI: 10.3390/nu11092152.
    [16]
    WANG R, HUANG X, ZHOU T, et al. Safety and feasibility of early oral nutrition after endoscopic treatment for patients with liver cirrhosis: A historical prospective and comparative effectiveness study[J]. JPEN J Parenter Enteral Nutr, 2022, 46( 7): 1660－ 1670. DOI: 10.1002/jpen.2328.
    [17]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34( 10): 2076－ 2089. DOI: 10.3969/j.issn.1001－5256.2018.10.007.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34( 10): 2076－ 2089. DOI: 10.3969/j.issn.1001－5256.2018.10.007.
    [18]
    BUSTAMANTE J, RIMOLA A, VENTURA PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis[J]. J Hepatol, 1999, 30( 5): 890－ 895. DOI: 10.1016/s0168－8278(99)80144－5.
    [19]
    FALLAHZADEH MA, RAHIMI RS. Hepatic encephalopathy and nutrition influences: A narrative review[J]. Nutr Clin Pract, 2020, 35( 1): 36－ 48. DOI: 10.1002/ncp.10458.
    [20]
    NARDELLI S, LATTANZI B, MERLI M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology, 2019, 70( 5): 1704－ 1713. DOI: 10.1002/hep.30692.
    [21]
    TAPPER EB, KONERMAN M, MURPHY S, et al. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index[J]. Am J Transplant, 2018, 18( 10): 2566－ 2570. DOI: 10.1111/ajt.15020.
    [22]
    LAI JC, RAHIMI RS, VERNA EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study[J]. Gastroenterology, 2019, 156( 6): 1675－ 1682. DOI: 10.1053/j.gastro.2019.01.028.
    [23]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33( 10): 1847－ 1863. DOI: 10.3969/j.issn.1001－5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33( 10): 1847－ 1863. DOI: 10.3969/j.issn.1001－5256.2017.10.003.
    [24]
    SCHLEICHER EM, KREMER WM, KALAMPOKA V, et al. Frailty as tested by the clinical frailty scale is a risk factor for hepatorenal syndrome in patients with liver cirrhosis[J]. Clin Transl Gastroenterol, 2022, 13( 7): e00512. DOI: 10.14309/ctg.0000000000000512.
    [25]
    CHAPMAN B, GOW P, SINCLAIR M, et al. Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant[J]. JHEP Rep, 2019, 1( 2): 107－ 113. DOI: 10.1016/j.jhepr.2019.05.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (510) PDF downloads(86) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return